Chiron Viagene, Inc.
Records under this name other than patents Chiron Viagene, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,241,982 | Method for treating brain cancer with a conditionally lethal gene Formerly held Term ended Term ended Jun 5, 2018 · USPTO record | Term ended | Term ended Jun 5, 2018 | USPTO record |
| US 6,133,029 | Replication defective viral vectors for infecting human cells Formerly held Term ended Term ended Oct 17, 2017 · USPTO record | Term ended | Term ended Oct 17, 2017 | USPTO record |
| US 6,013,517 | Crossless retroviral vectors Formerly held Term ended Term ended May 5, 2017 · USPTO record | Term ended | Term ended May 5, 2017 | USPTO record |
| US 6,015,686 | Eukaryotic layered vector initiation systems Formerly held Term ended Term ended Jan 18, 2017 · USPTO record | Term ended | Term ended Jan 18, 2017 | USPTO record |
| US 6,410,326 | Method for inhibiting human tumor cells Formerly held Lapsed on the fee record Ended Jun 25, 2014 · USPTO record | Lapsed on the fee record | Ended Jun 25, 2014 | USPTO record |
| US 6,569,679 | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene Formerly held Lapsed on the fee record Ended May 27, 2011 · USPTO record | Lapsed on the fee record | Ended May 27, 2011 | USPTO record |
| US 6,310,045 | Compositions and methods for cancer immunotherapy Formerly held Lapsed on the fee record Ended Oct 30, 2009 · USPTO record | Lapsed on the fee record | Ended Oct 30, 2009 | USPTO record |
| US 6,297,048 | Hepatitis therapeutics Formerly held Lapsed on the fee record Ended Oct 2, 2009 · USPTO record | Lapsed on the fee record | Ended Oct 2, 2009 | USPTO record |
| US 6,531,307 | Adenoviral vectors encoding a cytokine and a conditionally lethal gene Formerly held Lapsed on the fee record Ended Mar 11, 2007 · USPTO record | Lapsed on the fee record | Ended Mar 11, 2007 | USPTO record |
| US 6,495,349 | Chimeric gene constructs Formerly held Lapsed on the fee record Ended Dec 17, 2006 · USPTO record | Lapsed on the fee record | Ended Dec 17, 2006 | USPTO record |